From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.-S.L., D.C.L.), Lee Kong Chian School of Medicine, Nanyang Technological University (B.E.Y., Y.-S.L., D.C.L.), Yong Loo Lin School of Medicine (Y.-S.L., D.C.L.) and Saw Swee Hock School of Public Health (Y.-S.L.), National University of Singapore, and SingHealth Duke-NUS Global Health Institute (L.-F.W.) - all in Singapore.
N Engl J Med. 2021 Oct 7;385(15):1401-1406. doi: 10.1056/NEJMoa2108453. Epub 2021 Aug 18.
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern pose a challenge to the effectiveness of current vaccines. A vaccine that could prevent infection caused by known and future variants of concern as well as infection with pre-emergent sarbecoviruses (i.e., those with potential to cause disease in humans in the future) would be ideal. Here we provide data showing that potent cross-clade pan-sarbecovirus neutralizing antibodies are induced in survivors of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection who have been immunized with the BNT162b2 messenger RNA (mRNA) vaccine. The antibodies are high-level and broad-spectrum, capable of neutralizing not only known variants of concern but also sarbecoviruses that have been identified in bats and pangolins and that have the potential to cause human infection. These findings show the feasibility of a pan-sarbecovirus vaccine strategy. (Funded by the Singapore National Research Foundation and National Medical Research Council.).
新兴的严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）变种引起了人们对当前疫苗有效性的关注。一种能够预防已知和未来的变种引起的感染，以及预防新兴的沙贝科病毒（即那些未来有可能在人类中引起疾病的病毒）的疫苗将是理想的。在这里，我们提供的数据表明，在感染过严重急性呼吸系统综合征冠状病毒 1（SARS-CoV-1）并接种了 BNT162b2 信使 RNA（mRNA）疫苗的幸存者中，能够诱导出强效的跨属泛沙贝科病毒中和抗体。这些抗体具有高水平和广谱性，不仅能够中和已知的变种，还能够中和已在蝙蝠和穿山甲中发现的、具有引起人类感染潜力的沙贝科病毒。这些发现表明了泛沙贝科病毒疫苗策略的可行性。（由新加坡国家研究基金会和国家医学研究理事会资助）。
